1. HOME
2. Research Insight
3. Biosimilars Manufacturers - Sandoz (Switzerland), Mylan (USA, now Viatris) and Pfizer (USA) are the Key Manufacturers

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. The growth of this market is mainly driven by rising demand for biosimilars in developed and developing countries, favorable reimbursement policies and launch of novel biosimilars in the market.

The biosimilars market is highly competitive.

Major Biosimilars Market manufacturers include

• Sandoz (Switzerland),
• Celltrion (South Korea),
• Samsung Bioepis (South Korea),
• Mylan (USA, now Viatris),
• Biocon (India),
• Pfizer (USA) and many more....

These manufacturers, representing various countries, play pivotal roles in advancing biosimilar development, manufacturing, and commercialization, thereby expanding access to affordable biologic therapies and driving growth in the global biosimilars industry.

To know about the assumptions considered for the study download the pdf brochure

Sandoz (Switzerland):

Sandoz, a division of Novartis, is a leading global manufacturer of biosimilars. It has a diverse portfolio of biosimilar products, including versions of drugs like filgrastim, etanercept, and rituximab.

Role in Global Industry Growth: Sandoz has played a significant role in expanding access to biologic therapies through the development and commercialization of high-quality biosimilars. Its strategic partnerships, global manufacturing capabilities, and focus on regulatory compliance have contributed to the growth of the biosimilars market worldwide.

Celltrion (South Korea):

Celltrion is a South Korean biopharmaceutical company known for its expertise in biosimilar development. It has commercialized biosimilars of drugs like infliximab, rituximab, and trastuzumab.

Role in Global Industry Growth: Celltrion's innovation in biosimilar manufacturing processes, coupled with its commitment to quality and affordability, has positioned it as a key player in the global biosimilars market. Its competitive pricing strategies and partnerships with distribution networks have facilitated access to biosimilar therapies in various regions.

Samsung Bioepis (South Korea):

Samsung Bioepis, a subsidiary of Samsung Biologics, is a biopharmaceutical company specializing in the development and commercialization of biosimilar products. It has marketed biosimilars of drugs such as infliximab, etanercept, and adalimumab.

Role in Global Industry Growth: Samsung Bioepis has leveraged its parent company's expertise in biologics manufacturing to establish itself as a leading player in the biosimilars market. Its focus on innovation, quality assurance, and strategic partnerships has contributed to the expansion of biosimilar adoption worldwide.

Mylan (USA, now Viatris):

Mylan, now part of Viatris following a merger, is a global pharmaceutical company with a significant presence in the biosimilars market. It offers biosimilar versions of drugs like adalimumab, trastuzumab, and insulin glargine.

Role in Global Industry Growth: Mylan's strategic acquisitions and partnerships have bolstered its biosimilars portfolio and market presence. Its focus on increasing patient access to affordable biologic therapies, particularly in emerging markets, has supported the growth of the biosimilars industry globally.

Biocon (India):

Biocon, headquartered in India, is a biopharmaceutical company with expertise in biosimilar development and manufacturing. It has commercialized biosimilars of drugs such as insulin glargine, trastuzumab, and pegfilgrastim.

Role in Global Industry Growth: Biocon's vertically integrated business model, encompassing research, development, manufacturing, and commercialization of biosimilars, has positioned it as a key player in the global biosimilars market. Its focus on quality, affordability, and regulatory compliance has facilitated market penetration in diverse.

Pfizer (USA):

Pfizer, a multinational pharmaceutical company based in the USA, has entered the biosimilars market with products such as biosimilar versions of infliximab, filgrastim, and epoetin alfa.

Role in Global Industry Growth: Pfizer's entry into the biosimilars market has provided additional competition and choice for patients and healthcare systems. Its extensive global network, regulatory expertise, and brand reputation have contributed to the growth and acceptance of biosimilars worldwide.

Related Reports:

Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region – Global Forecast to 2028